2014
Back in March this year, we posted a blog about biological therapies for stomach cancer with a focus on the drug Ramicurumab. It has been recently announced that this drug has now been licensed in the USA. The FDA (the organization that assesses new drugs) has approved Ramicurumab for use in patients with stage 4 stomach cancer.
Our specialist Dr Nick Maisey comments: “Although stomach cancer can still be a difficult disease to treat, this is a significant step forward and heralds the introduction of targeted therapy for patients with this disease.”
For more information about Stomach cancer visit the Macmillan Cancer website